Quick Answer
Lucid Diagnostics Inc. reported Total Revenue of $4.35 million for fiscal year 2024.
Lucid Diagnostics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $4.35M +79.0% |
$2.43M +544.0% |
$377.0K -24.6% |
$500.0K | — |
| Net Income | -$58.01M -27.4% |
-$45.53M +13.6% |
-$52.67M +6.2% |
-$56.17M -100.1% |
-$28.08M -239.1% |
-$8.28M |
| Diluted EPS | — | -$1.05 +16.7% |
-$1.26 +18.7% |
-$1.55 | — | — |
| Total Assets | $40.45M +31.7% |
$30.71M +12.6% |
$27.27M -16.1% |
$32.51M -44.9% |
$59.00M +2587.9% |
$2.19M |
| Cash and Equivalents | — | $22.36M +18.3% |
$18.90M -15.9% |
$22.47M -58.1% |
$53.66M | — |
| Stockholders Equity | $10.94M +102.9% |
$5.39M +333.3% |
-$2.31M -110.0% |
$23.05M -57.9% |
$54.74M +504.9% |
-$13.52M -154.6% |
| R&D Expense | $5.68M -5.2% |
$5.99M -17.4% |
$7.25M -35.6% |
$11.26M +21.1% |
$9.30M +70.8% |
$5.44M |
| Operating Income | -$49.64M -7.8% |
-$46.05M +5.0% |
-$48.48M +13.8% |
-$56.25M -105.2% |
-$27.42M -231.1% |
-$8.28M |
| Gross Profit | — | — | — | $377.0K -24.6% |
$500.0K | — |
| Shares Outstanding | 131.10M +107.9% |
63.07M +49.0% |
42.33M +4.5% |
40.52M +16.0% |
34.92M +147.4% |
14.11M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.21M | +3.3% | +4.1% |
| Net Income | September 30, 2025 | -$10.40M | +16.0% | -134.2% |
| Diluted EPS | September 30, 2025 | -$0.10 | +60.0% | -25.0% |
| Total Assets | September 30, 2025 | $53.20M | +135.4% | +37.6% |
| Cash and Equivalents | September 30, 2025 | $47.33M | +226.7% | +52.1% |
| Stockholders Equity | September 30, 2025 | $25.84M | +307.6% | +228.6% |
| R&D Expense | September 30, 2025 | $1.27M | -23.6% | +1.4% |
| Operating Income | September 30, 2025 | -$11.76M | -0.6% | -3.3% |
| Gross Profit | September 30, 2022 | $76.0K | -62.0% | +142.2% |
| Shares Outstanding | September 30, 2025 | 130.92M | +153.7% | +28.6% |
- Lucid Diagnostics Inc. reported Total Revenue of $4.35 million for fiscal year 2024.
- Lucid Diagnostics Inc. showed an increase of +79.0% in Total Revenue compared to the prior fiscal year.
- Lucid Diagnostics Inc. reported Net Income of -$58.01 million for fiscal year 2025.
- Lucid Diagnostics Inc. showed a decrease of -27.4% in Net Income compared to the prior fiscal year.
- Lucid Diagnostics Inc. reported Diluted EPS of $1.05 per share (loss) for fiscal year 2024.
- Lucid Diagnostics Inc. showed an increase of +16.7% in Diluted EPS compared to the prior fiscal year.
- Lucid Diagnostics Inc. reported Total Assets of $40.45 million for fiscal year 2025.
- Lucid Diagnostics Inc. showed an increase of +31.7% in Total Assets compared to the prior fiscal year.
- Lucid Diagnostics Inc. reported Cash and Equivalents of $22.36 million for fiscal year 2024.
- Lucid Diagnostics Inc. showed an increase of +18.3% in Cash and Equivalents compared to the prior fiscal year.
- Lucid Diagnostics Inc. reported Stockholders Equity of $10.94 million for fiscal year 2025.
- Lucid Diagnostics Inc. showed an increase of +102.9% in Stockholders Equity compared to the prior fiscal year.
- Lucid Diagnostics Inc. reported R&D Expense of $5.68 million for fiscal year 2025.
- Lucid Diagnostics Inc. showed a decrease of -5.2% in R&D Expense compared to the prior fiscal year.
- Lucid Diagnostics Inc. reported Operating Income of -$49.64 million for fiscal year 2025.
- Lucid Diagnostics Inc. showed a decrease of -7.8% in Operating Income compared to the prior fiscal year.
- Lucid Diagnostics Inc. reported Gross Profit of $377.0 thousand for fiscal year 2022.
- Lucid Diagnostics Inc. showed a decrease of -24.6% in Gross Profit compared to the prior fiscal year.
- Lucid Diagnostics Inc. reported Shares Outstanding of 131.10 million shares for fiscal year 2025.
- Lucid Diagnostics Inc. showed an increase of +107.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: